FindMyKOL
Clinical trialNCT00501995CompletedPhase 3Interventional

High Dose Cyclophosphamide for Treatment of Scleroderma

NCT00501995 is a phase 3 interventional trial sponsored by Johns Hopkins University. As of 18 Nov 2026, it is completed. It studies Cyclophosphamide in Scleroderma. The registry lists an enrollment of 6 participants. The registry lists a start date of 28 Feb 2001 and a primary completion date of 31 Jul 2008.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00501995
FieldValue
Registry IDNCT00501995
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorJohns Hopkins University
Enrollment6
ConditionsScleroderma
DrugsCyclophosphamide
Start28 Feb 2001
Primary completion31 Jul 2008
Study completion31 May 2010
Last update posted14 Jun 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Systemic Sclerosis (Scleroderma) varies greatly in clinical manifestations, mode of presentation, and course. The natural history of this chronic autoimmune disease ranges from benign to fatal. Patients are classified into limited and diffuse scleroderma defined by the degree of skin involvement. Patients with limited disease (e.g. the C.R.E.S.T. syndrome) generally have mild disease and normal survival. However, patients with diffuse cutaneous scleroderma often have severe multi-system disease that is not only devastating emotionally and physically but is associated with a 60-70% five year survival and a 40-50% 10 year survival. No therapies have proven effective in the treatment of scleroderma. Strategy to treat scleroderma have included attempts to prevent fibrosis with drugs that interfere with collagen metabolism, attempts to modify the disease process by immunosuppression and attempts to alter the disease by vasoactive drugs. High dose of corticosteroids and other immunosuppressive drugs (e.g. chlorambucil, 5-fluorouracil, methotrexate, cyclophosphamide, cyclosporine) used at conventional doses have not proven curative, but have shown some benefit for inflammatory features of the disease (e.g. arthritis, myositis, fibrosing alveolitis). Both allogeneic and autologous bone marrow transplantation (BMT) have shown to modify and in some instances reverse a variety of animal models of autoimmune disease. This has prompted many investigators to propose the use of peripheral blood stem cell transplantation (PBSCT) for the treatment of autoimmune disease including scleroderma. Unfortunately, this approach risks infusing untreated autoreactive lymphocyte clones after the immunoablative preparative regimen. We have previously demonstrated that high-dose cyclophosphamide without BMT can induce durable and complete remissions in another autoimmune disease, severe aplastic anemia. Recent data with high dose cyclophosphamide show that it can induce complete remissions in other autoimmune hematologic disorders. The objective of this study is to determine whether high dose cyclophosphamide can induce a durable remission in scleroderma patients with life-threatening disease, and to determine toxicity of high dose cyclophosphamide in high risk scleroderma patients.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00501995

Each answer restates registry values shown on this page.

What is NCT00501995?

NCT00501995 is a phase 3 interventional trial sponsored by Johns Hopkins University. It studies Cyclophosphamide in Scleroderma.

Who leads NCT00501995?

The registry names Fredrick M Wigley, MD (principal investigator, Johns Hopkins University) as the overall official.

Which drugs does NCT00501995 study?

The registered drug and biological interventions are Cyclophosphamide.

When did NCT00501995 end?

The registry lists a primary completion date of 31 Jul 2008 and a study completion date of 31 May 2010. The sponsor last updated the record on 14 Jun 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.